Advertisement

Der Urologe

, Volume 52, Issue 9, pp 1265–1269 | Cite as

Seminom klinisches Stadium I

Neuer Therapiestandard Surveillance?
  • F. Zengerling
  • J. Müller
  • A.J. Schrader
  • M. SchraderEmail author
Übersichten

Zusammenfassung

Hintergrund

Die Therapie des Seminoms im klinischen Stadium I ist einem steten Wandel unterworfen. Wurden Surveillance, adjuvante Strahlentherapie und adjuvante Chemotherapie bis vor wenigen Jahren als weitgehend gleichberechtigte Therapiealternativen angesehen, machen aktuell publizierte Studien eine differenziertere Betrachtungsweise notwendig.

Diskussion

Die Übersicht diskutiert die jüngsten Daten zu möglichen Spätfolgen adjuvanter Strahlen- und Chemotherapie, die Frage einer Risikostratifizierung sowie die Vorteile und Limitationen einer Surveillancestrategie.

Schlüsselwörter

Therapie, adjuvante Langzeittoxizität  Risikostratifizierung Hodentumor Metastasierung 

Clinical stage I seminoma

Is surveillance a new therapy standard?

Abstract

Background

The therapy of stage I seminoma is under constant change. While surveillance, adjuvant radiotherapy and adjuvant chemotherapy were seen as equal therapeutic alternatives up to a few years ago, recently published studies make it necessary to adopt a more differentiated approach.

Discussion

In this review, recent data on the long-term effects of adjuvant radiotherapy and chemotherapy, the question of risk stratification as well as the advantages and limitations of a surveillance strategy are discussed.

Keywords

Therapy, adjuvant Long-term toxicity Risk stratification Testicular cancer Metastasis 

Notes

Einhaltung ethischer Richtlinien

Interessenkonflikt. F. Zengerling, J. Müller, A.J. Schrader und M. Schrader geben an, dass kein Interessenkonflikt besteht. Dieser Beitrag beinhaltet keine Studien an Menschen oder Tieren.

Literatur

  1. 1.
    Andreassen KE, Grotmol T, Cvancarova MS et al (2011) Risk of metachronous contralateral testicular germ cell tumors: a population-based study of 7,102 Norwegian patients (1953–2007). Int J Cancer 129(12):2867–2874PubMedCrossRefGoogle Scholar
  2. 2.
    Aparicio J, Maroto P, Muro XG del et al (2011) Risk-adapted treatment in clinical stage I testicular seminoma: the third Spanish Germ Cell Cancer Group study. J Clin Oncol 29(35):4677–4681PubMedCrossRefGoogle Scholar
  3. 3.
    Arai E, Nakagawa T, Wakai-Ushijima S et al (2012) DNA methyltransferase 3B expression is associated with poor outcome of stage I testicular seminoma. Histopathology 60(6B):12–18CrossRefGoogle Scholar
  4. 4.
    Beyer J, Albers P, Altena R et al (2013) Maintaining success, reducing treatment burden, focusing on survivorship: highlights from the third European consensus conference on diagnosis and treatment of germ-cell cancer. Ann Oncol 24(4):878–888PubMedCrossRefGoogle Scholar
  5. 5.
    Brabrand S, Fossa SD, Cvancarova M et al (2012) Probability of metachronous testicular cancer in patients with biopsy-proven intratubular germ cell neoplasia depends on first-time treatment of germ cell cancer. J Clin Oncol 30(32):4004–4010PubMedCrossRefGoogle Scholar
  6. 6.
    Cafferty FH, Gabe R, Huddart RA et al (2012) UK management practices in stage I seminoma and the Medical Research Council Trial of Imaging and Schedule in Seminoma Testis managed with surveillance. Clin Oncol (R Coll Radiol) 24(1):25–29Google Scholar
  7. 7.
    Chung P (2010) Prognostic factors for relapse in stage I seminoma managed with surveillance: a validation study. J Clin Oncol 28:15CrossRefGoogle Scholar
  8. 8.
    Cummins S, Yau T, Huddart R et al (2010) Surveillance in stage I seminoma patients: a long-term assessment. Eur Urol 57(4):673–678PubMedCrossRefGoogle Scholar
  9. 9.
    Dieckmann KP, Wilken S, Loy V et al (2013) Treatment of testicular intraepithelial neoplasia (intratubular germ cell neoplasia unspecified) with local radiotherapy or with platinum-based chemotherapy: a survey of the German Testicular Cancer Study Group. Ann Oncol 24(5):1332–1337PubMedCrossRefGoogle Scholar
  10. 10.
    Germa-Lluch JR, Garcia del Muro X, Maroto P et al (2002) Clinical pattern and therapeutic results achieved in 1490 patients with germ-cell tumours of the testis: the experience of the Spanish Germ-Cell Cancer Group (GG). Eur Urol 42(6):553–562PubMedCrossRefGoogle Scholar
  11. 11.
    Hallemeier C (2013) Late gastrointestinal (GI) complications in patients with stage I-II testicular seminoma treated with radiotherapy (RT). J Clin Oncol 30(Suppl):4595Google Scholar
  12. 12.
    Honecker F, Wermann H, Mayer F et al (2009) Microsatellite instability, mismatch repair deficiency, and BRAF mutation in treatment-resistant germ cell tumors. J Clin Oncol 27(13):2129–2136PubMedCrossRefGoogle Scholar
  13. 13.
    Horwich A, Shipley J, Huddart R (2006) Testicular germ-cell cancer. Lancet 367(9512):754–765PubMedCrossRefGoogle Scholar
  14. 14.
    Kohut R (2012) 661 Stage I seminoma trends in utilization of adjuvant therapy following orchiectomy using the national cancer database. J Urol 187(4 Suppl):269–270CrossRefGoogle Scholar
  15. 15.
    Krege S, Beyer J, Souchon R et al (2008) European consensus conference on diagnosis and treatment of germ cell cancer: a report of the second meeting of the European Germ Cell Cancer Consensus group (EGCCCG): part I. Eur Urol 53(3):478–496PubMedCrossRefGoogle Scholar
  16. 16.
    Leung E (2010) Total treatment burden in stage I seminoma patients. J Clin Oncol 28:15s (suppl; abstr 4534)CrossRefGoogle Scholar
  17. 17.
    Lewinshtein D, Gulati R, Nelson PS et al (2011) Incidence of second malignancies after external beam radiotherapy for clinical stage I testicular seminoma. BJU Int 109(5):706–712PubMedCrossRefGoogle Scholar
  18. 18.
    Links PS, Stockwell ML (1985) Obstacles in the prevention of psychological sequelae in survivors of childhood cancer. Am J Pediatr Hematol Oncol 7(2):132–140PubMedGoogle Scholar
  19. 19.
    Mortensen M (2013) A nationwide cohort study of surveillance for stage I seminoma. J Clin Oncol 31(Suppl):4502Google Scholar
  20. 20.
    Oliver RT, Mason MD, Mead GM et al (2005) Radiotherapy versus single-dose carboplatin in adjuvant treatment of stage I seminoma: a randomised trial. Lancet 366(9482):293–300PubMedCrossRefGoogle Scholar
  21. 21.
    Oliver RT, Mead GM, Rustin GJ et al (2011) Randomized trial of carboplatin versus radiotherapy for stage I seminoma: mature results on relapse and contralateral testis cancer rates in MRC TE19/EORTC 30982 study (ISRCTN27163214). J Clin Oncol 29(8):957–962PubMedCrossRefGoogle Scholar
  22. 22.
    Powles T, Robinson D, Shamash J et al (2008) The long-term risks of adjuvant carboplatin treatment for stage I seminoma of the testis. Ann Oncol 19(3):443–447PubMedCrossRefGoogle Scholar
  23. 23.
    Ruf CG, Isbarn H, Wagner W et al (2013) Changes in epidemiologic features of testicular germ cell cancer: age at diagnosis and relative frequency of seminoma are constantly and significantly increasing(). Urol Oncol 2013(6):00465–00466Google Scholar
  24. 24.
    Rusner C, Trabert B, Katalinic A et al (2013) Incidence patterns and trends of malignant gonadal and extragonadal germ cell tumors in Germany, 1998–2008. Cancer Epidemiol 37(4):370–373PubMedCrossRefGoogle Scholar
  25. 25.
    Sharda NN, Kinsella TJ, Ritter MA (1996) Adjuvant radiation versus observation: a cost analysis of alternate management schemes in early-stage testicular seminoma. J Clin Oncol 14(11):2933–2939PubMedGoogle Scholar
  26. 26.
    Simone CB 2nd, Kramer K, O’Meara WP et al (2012) Predicted rates of secondary malignancies from proton versus photon radiation therapy for stage I seminoma. Int J Radiat Oncol Biol Phys 82(1):242–249PubMedCrossRefGoogle Scholar
  27. 27.
    Skoogh J, Steineck G, Johansson B et al (2013) Psychological needs when diagnosed with testicular cancer: findings from a population-based study with long-term follow-up. BJU Int 111(8):1287–1293PubMedCrossRefGoogle Scholar
  28. 28.
    Tandstad T, Smaaland R, Solberg A et al (2011) Management of seminomatous testicular cancer: a binational prospective population-based study from the Swedish norwegian testicular cancer study group. J Clin Oncol 29(6):719–725PubMedCrossRefGoogle Scholar
  29. 29.
    Tarin TV, Sonn G, Shinghal R (2009) Estimating the risk of cancer associated with imaging related radiation during surveillance for stage I testicular cancer using computerized tomography. J Urol 181(2):627–632PubMedCrossRefGoogle Scholar
  30. 30.
    Travis LB, Fossa SD, Schonfeld SJ et al (2005) Second cancers among 40,576 testicular cancer patients: focus on long-term survivors. J Natl Cancer Inst 97(18):1354–1365PubMedCrossRefGoogle Scholar
  31. 31.
    Walraven C van, Fergusson D, Earle C et al (2011) Association of diagnostic radiation exposure and second abdominal-pelvic malignancies after testicular cancer. J Clin Oncol 29(21):2883–2888PubMedCrossRefGoogle Scholar
  32. 32.
    Wanderas EH, Fossa SD, Tretli S (1997) Risk of subsequent non-germ cell cancer after treatment of germ cell cancer in 2006 Norwegian male patients. Eur J Cancer 33(2):253–262PubMedCrossRefGoogle Scholar
  33. 33.
    Warde P, Specht L, Horwich A et al (2002) Prognostic factors for relapse in stage I seminoma managed by surveillance: a pooled analysis. J Clin Oncol 20(22):4448–4452PubMedCrossRefGoogle Scholar
  34. 34.
    Yu HY, Madison RA, Setodji CM et al (2009) Quality of surveillance for stage I testis cancer in the community. J Clin Oncol 27(26):4327–4332PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2013

Authors and Affiliations

  • F. Zengerling
    • 1
  • J. Müller
    • 1
  • A.J. Schrader
    • 1
  • M. Schrader
    • 1
    Email author
  1. 1.Klinik für Urologie und KinderurologieUniversitätsklinikum UlmUlmDeutschland

Personalised recommendations